Virax Biolabs Group Limited

NasdaqCM:VRAX Stock Report

Market Cap: US$1.9m

Virax Biolabs Group Valuation

Is VRAX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VRAX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VRAX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VRAX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRAX?

Other financial metrics that can be useful for relative valuation.

VRAX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does VRAX's PS Ratio compare to its peers?

The above table shows the PS ratio for VRAX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.3x
GPOX GPO Plus
1.4xn/aUS$4.5m
ACBM Acro Biomedical
17.5xn/aUS$6.3m
SKYI Sky Century Investment
10.1xn/aUS$755.1k
FZMD Fuse Medical
0.3xn/aUS$5.8m
VRAX Virax Biolabs Group
23.3xn/aUS$1.9m

Price-To-Sales vs Peers: VRAX is expensive based on its Price-To-Sales Ratio (23.3x) compared to the peer average (7.3x).

Price to Earnings Ratio vs Industry

How does VRAX's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.2%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.2%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: VRAX is expensive based on its Price-To-Sales Ratio (23.3x) compared to the US Healthcare industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is VRAX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRAX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VRAX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.